In This Issue
207 In This Issue of Diabetes Care

Perspectives in Care
209 The National Diabetes Education Program at 20 Years: Lessons Learned and Plans for the Future
L.M. Siminerio, A. Albright, J. Fradkin, J. Galliván, J. McDvitt, B. Rodríguez, D. Tuncer, and F. Wong
219 Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect
S. Sussia

Commentary
241 The Role of Diabetes Care and Its Contributions to the Field of Diabetes: A Profile in Progress
L. Reynolds and S.M. Genuith

Clinical Care/Education/Nutrition/Psychosocial Research
255 Five-Year Cost-effectiveness of the Multidisciplinary Risk Assessment and Management Programme—Diabetes Mellitus (RAMP-DM)
258 Efficacy and Safety of Once-weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
267 Predictors of Quality of Life and Other Patient-reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes
C. Bradley, E. Eschwège, P. de Pablos-Velasco, K.G. Parhofer, D. Simon, H. Vandenberghe, and L. Gönder-Frederick

Epidemiology/Health Services Research
277 Interaction of Dietary and Genetic Factors Influencing Body Iron Status and Risk of Type 2 Diabetes Within the EPIC-InterAct Study
286 Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies
M. Boniol, M. Franchi, M. Bota, A. Leclercq, J. Guillaum, N. van Damme, G. Corrao, P. Autier, and P. Boyle
N.R. Burrows, Y. Li, E.W. Gregg, and L.S. Geiss

Emerging Technologies and Therapeutics
303 Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes

Pathophysiology/Complications
311 TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes
318 Comparison of β-Cell Function Between Overweight/Obese Adults and Adolescents Across the Spectrum of Glycemia
326 Revisiting the Relationships Between Measures of Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring Data Sets
M. Gimenez, A.J. Tannen, M. Reddy, V. Moscardo, I. Conger, and N. Oliver

Cardiovascular and Metabolic Risk
333 Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
J. Rosenstock, J.B. Buse, R. Azeem, P. Prabhakar, L. Kjems, H. Huang, and M.A. Baron
341 Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission
348 Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD
356 How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Novel Communications in Diabetes
364 Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years
L.S.F. de Carvalho, A.M. Campos, and A.C. Sposito

368 Increased Liver Fatty Acid Uptake Is Partly Reversed and Liver Fat Content Normalized After Bariatric Surgery
H. Immonen, J.C. Hannukainen, N. Kudomi, J. Pihlajamäki, V. Saunavaara, J. Laine, P. Salminen, T. Lehtimäki, T. Pham, P. Iozzo, and P. Nuutila

Meta-analysis
372 Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
A. Mantovani, C.D. Byrne, E. Bonora, and G. Targher

Issues and Events
383 Issues and Events

e-Letters – Observations
374 Morning Enzymatic Activity of DPP-4 Is Differentially Altered by Sleep Loss in Women and Men

e12 Obstructive Sleep Apnea and Diabetes Independently Add to Cardiovascular Risk After Coronary Revascularization

e15 Twin Pregnancy With Gestational Diabetes Mellitus: A Double Whammy?
S. Ooi and V.W. Wong

e-Letters – Comments and Responses
Diabetes Care 2017;40:1425–1432
D. Giugliano, M.I. Maiorino, G. Bellastella, and K. Esposito

Diabetes Care 2017;40:1425–1432
S.V. Edelman and W.H. Polonsky

382 Comment on Lent et al. All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes.
Diabetes Care 2017;40:1379–1385
A.E. Pontiroli and A.S. Zakaria

384 Response to Comment on Lent et al. All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes.
Diabetes Care 2017;40:1379–1385
M.R. Lent, P.N. Benotti, and G.C. Wood